Résumé :
|
[BDSP. Notice produite par INIST-CNRS R0xCB2PW. Diffusion soumise à autorisation]. The authors quantified improvement in predicting cutaneous malignant melanoma, basal cell carcinoma, and squamous cell carcinoma of the skin made possible by information on common variants of the melanocortin-1 receptor gene (MC1R) in a 1998-1999 population-based case-control study of subjects aged 20-59 years of northern European ancestry in Tasmania, Australia. Melanin density at the upper inner arm was estimated by spectrophotometry. DNA samples were genotyped for five MC1R variants : Val60Leu, Asp84Glu, Arg151Cys, Arg160Trp, and Asp294His. Among controls (n=267), variant carriers, versus noncarriers, had lower (p<0.01) mean melanin concentrations. Increased risk conferred by genotype was restricted mainly to those with the darkest skins : for subjects with at least 2% melanin, the odds of carrying each additional variant were higher for cutaneous malignant melanoma (n=39 ; odds ratio=1.45,95% confidence interval : 0.87,2.44), basal cell carcinoma (n=35 ; odds ratio=1.86,95% confidence interval : 1.14,3.02), and squamous cell carcinoma (n=42 ; odds ratio=2.67,95% confidence interval : 1.50,4.74) cases than for controls (n=135). Adding MC1R information to prediction based on age, sex, and cutaneous melanin increased the area under the receiver operating characteristic curve by 1.4% (cutaneous malignant melanoma), 3.2% (basal cell carcinoma), or 2.0% (squamous cell carcinoma). The improvement in prediction was probably too small to be valuable in a clinical setting.
|